Rising Regulations And Cost Pressures Will Limit Pharma Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 17 Analysts
Published
29 Jun 25
Updated
09 Aug 25
AnalystLowTarget's Fair Value
₹1,106.00
25.1% overvalued intrinsic discount09 Aug
₹1,383.50
1Y
-0.06%7D
0.5%